Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides
ABSTRACT Mycosis fungoides (MF), the most common subtype of cutaneous T cell lymphoma (CTCL), has a poor prognosis in advanced stages. Brentuximab vedotin (BV), a CD30‐targeting antigen‐drug conjugate approved for CD30+ MF following prior systemic treatment, still exhibits resistance with unclarifie...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2026-05-01
|
| Colección: | Advanced Science |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1002/advs.202517353 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|